Reuters logo
BRIEF-Atara Biotherapeutics reports positive interim early-stage data on multiple sclerosis drug
April 20, 2017 / 8:38 PM / 8 months ago

BRIEF-Atara Biotherapeutics reports positive interim early-stage data on multiple sclerosis drug

April 20 (Reuters) - Atara Biotherapeutics Inc-

* Atara Bio announces positive interim results from ongoing phase 1 trial of the autologous version of ata188 in patients with primary and secondary progressive multiple sclerosis (ms) at the american academy of neurology (aan) annual meeting 2017

* Atara Biotherapeutics Inc - look forward to further development of autologous ata188 for patients with ms

* Atara Biotherapeutics Inc - expected initiation of both phase 1 allogeneic ata188 trial as well as our phase 3 trials of ata129 in second half of year.

* Atara Biotherapeutics Inc - no patient in trial experienced progression of disability; there was no worsening in edss Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below